Suchergebnisse - %22Virus Diseases%22

PubPharm (352)

1

Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model

enthalten in: Human gene therapy | 2024

von Hayashi, Y. | Sehara, Y. | Watano, R. | +5

2

Nuclear ribonucleoprotein RALY downregulates foot-and-mouth disease virus replication but antagonized by viral 3C protease

enthalten in: Microbiology spectrum | 2024

von Wu, J. | Sun, C. | Guan, J. | +6

3

Immunological effects of ractopamine in rabbits receiving the viral inactivated rabbit hemorrhagic disease vaccine

enthalten in: Open veterinary journal | 2024

von Shams, G. | Ibrahim, H. | Hassan, H. | +2

4

Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in α-galactosidase A-deficient mice

enthalten in: The journal of gene medicine | 2023

von Hayashi, Y. | Sehara, Y. | Watano, R. | +5

5

Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus

enthalten in: Circulation | 2023

von Zhou, H. | Yang, J. | Srinath, C. | +23

6

Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells

enthalten in: Veterinary and comparative oncology | 2023

von Wang, J. | Li, M. | Li, M.

7

Foot-and-Mouth Disease Virus Induces Porcine Gasdermin E-Mediated Pyroptosis through the Protease Activity of 3Cpro

enthalten in: Journal of virology | 2023

von Ren, X. | Yin, M. | Zhao, Q. | +5

8

Simultaneous Expression of Chicken Granulocyte Monocyte Colony-Stimulating Factor and the Hemagglutinin-Neuraminidase Epitope of the Virulent Newcastle Disease Virus Genotype VII C22 Strain in a Functional Synthetic Recombinant Adenovirus as a Genotype-Matched Vaccine with Potential Antiviral Activity

enthalten in: Microbiology spectrum | 2023

von Adam, F. | Zhao, X. | Guan, Z. | +13

9

Multicenter, Open Label, Randomized Study of 48 Weeks to Compare the Safety, Tolerability and Efficacy of 800 mg twice daily of Indinavir Sulfate, 100 mg twice a day of Ritonavir and Two New Nucleoside Reverse Transcriptase Inhibitors ( NRTIs) versus 1250 mg twice daily of Nelfinavir and Two New NRTls in virgin patients of Protease Inhibitor (Pl). : Multicenter, Open Label, Randomized Study of 48 Weeks to Compare the Safety, Tolerability and Efficacy of 800 mg twice daily of Indinavir Sulfate, 100 mg twice a day of Ritonavir and Two New Nucleoside Reverse Transcriptase Inhibitors ( NRTIs) versus 1250 mg twice daily of Nelfinavir and Two New NRTls in virgin patients of Protease Inhibitor (Pl).

enthalten in: WHO International Clinical Trials Registry Platform | 2023

10

A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each in Combination with Fixed Dose Zidovudine-Lamivudine : A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each in Combination with Fixed Dose Zidovudine-Lamivudine

enthalten in: WHO International Clinical Trials Registry Platform | 2023

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[36]